Related Experiment Video
Updated: Jan 23, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.2K
Modest, at best: The effect of getting rid of copays for antiplatelet drugs
Managed Care (Langhorne, Pa.)
|June 13, 2019
Insights
Eliminating copays improved adherence to antiplatelet therapy. However, this did not lead to a reduction in major cardiovascular events for patients adhering to the medication.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Pharmacoeconomics
Background:
- Adherence to antiplatelet therapy is crucial for preventing cardiovascular events.
- Medication copays can be a significant barrier to patient adherence.
Purpose of the Study:
- To determine if eliminating copays enhances adherence to antiplatelet therapy.
- To assess the impact of improved adherence on major cardiovascular events.
Main Methods:
- A study design was implemented to compare adherence rates before and after copay elimination.
- Patient outcomes, specifically major cardiovascular events, were monitored.
Main Results:
- Eliminating copays was shown to significantly improve adherence to antiplatelet therapy.
- Despite increased adherence, no statistically significant reduction in major cardiovascular events was observed.
Conclusions:
- While cost reduction strategies like copay elimination can boost medication adherence, they may not directly translate to improved clinical cardiovascular outcomes.
- Further research is needed to understand the complex interplay between cost, adherence, and clinical event reduction in antiplatelet therapy.
Abstract:
A study designed to test whether eliminating copays would improve adherence to antiplatelet therapy showed that, yes, indeed, it does. But the results also showed no reduction in major cardiovascular events among those who stuck with the medication.
Keywords:
Insurance, Pharmaceutical ServicesMore Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:25Pharmacokinetics: Drug–Drug Interactions
394
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
394
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
154
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
154
01:26FDA Approved Drugs: Changes to Approved Drugs
248
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
248
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.1K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
462
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
462